NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Revenue of NRx Pharmaceuticals, Inc. (NRXP)
Revenue in 2023 (TTM): $
According to NRx Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of NRx Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-5,000 | $-30,025,000 | $-30,159,000 | $-30,150,000 |
| 2022 | $ | $-4,000 | $-39,750,000 | $-39,816,000 | $-35,235,000 |
| 2021 | $ | $-2,000 | $-93,043,000 | $-93,063,000 | $-71,715,000 |
| 2020 | $ | $-907,406 | $-51,719,000 | $-51,777,000 | $-12,347,000 |
| 2019 | $ | $ | $-713,187 | $492.63 K | $408.43 K |
| 2018 | $ | $-1,006,503 | $82.41 K | $82.41 K | $66.1 K |
| 2017 | $ | $ | $-105,036 | $-105,033 | $-105,033 |